Quick Answer
Breast cancer treatment research is moving toward more specific, measurable biological categories. Four important directions are HER2-low and HER2-ultralow treatment, ESR1 mutation-guided endocrine therapy, tumor-immune biology, and therapeutic strategies built around DNA-repair vulnerabilities.
Breast cancer treatment is increasingly shaped by a simple idea: a useful treatment category should reflect something measurable about the cancer.
That principle has driven HER2-targeted treatment for decades, but the same logic is now expanding into more refined biomarker groups, acquired resistance mutations, immune biology, and DNA-repair vulnerabilities.
The result is not one new “cure,” but a growing ability to divide broad breast cancer categories into more specific biological questions. NCI: Advances in Breast Cancer Research
1. HER2 Is Becoming More Than a Positive-or-Negative Label
Historically, HER2 testing was used largely to distinguish HER2-positive cancers from cancers that did not meet that threshold. Research into antibody–drug conjugates has complicated that binary view.
Trastuzumab deruxtecan, for example, links a HER2-targeting antibody to a cytotoxic payload. Preclinical research suggested that properties beyond simply recognizing HER2—including payload delivery and activity in heterogeneous models—could influence response.
Clinical development subsequently extended HER2-directed treatment into populations with lower levels of HER2 expression. In January 2025, the FDA approved trastuzumab deruxtecan for a defined group of patients with unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer after progression on endocrine therapy in the metastatic setting. FDA approval notice
This does not mean every HER2-negative tumor is now considered HER2-positive. Instead, it illustrates how a biomarker that once appeared mainly binary can acquire additional treatment-relevant categories as new therapies are developed.
What researchers still need to understand
- how much target expression is needed for a particular treatment
- how heterogeneous that expression is within the tumor
- why apparently similar tumors respond differently
These questions can be investigated using cell models, tissue studies, molecular measurements, and treatment-response experiments before being tested clinically.
2. Resistance Mutations Are Becoming Treatment Biomarkers
Hormone receptor–positive breast cancer provides another example. Endocrine therapies can suppress estrogen production or interfere with estrogen receptor signaling. But cancer cells can evolve under treatment pressure.
One important mechanism involves ESR1, the gene encoding estrogen receptor alpha. Certain acquired ESR1 mutations can allow estrogen receptor signaling to remain active despite reduced estrogen availability, contributing to resistance to some endocrine approaches.
This biology has already influenced treatment selection. Elacestrant was approved in 2023 for defined patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after prior endocrine therapy. FDA: Elacestrant approval
In September 2025, FDA approved imlunestrant for another defined ESR1-mutated population. FDA: Imlunestrant approval
On September 18, 2026, FDA also approved imlunestrant in combination with abemaciclib for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. FDA: Imlunestrant + abemaciclib approval
The important research story is not the growing list of drugs. It is that a mutation that can emerge during treatment can itself become information used to guide the next treatment strategy.
3. Immunotherapy Asks a Different Biological Question
Targeted therapy usually begins with a feature of the cancer cell. Immunotherapy asks another question: can the relationship between the tumor and the immune system be changed?
Checkpoint inhibitors interfere with signals that can restrain immune responses. In breast cancer, this strategy has become clinically relevant particularly in selected triple-negative disease settings.
Research in this area therefore needs to examine more than tumor-cell growth alone. Scientists may investigate immune-cell populations, tumor–immune interactions, cytokine signaling, biomarker expression, and how the tumor microenvironment changes after treatment. NCI: Immunotherapy for Breast Cancer
This is one reason breast cancer research increasingly uses more complex models alongside conventional cancer-cell cultures.
4. DNA Repair Can Turn a Weakness Into a Therapeutic Opportunity
BRCA1 and BRCA2 normally contribute to DNA repair. When these repair pathways are impaired, the resulting genomic instability can increase cancer risk—but the same defect can also create a vulnerability.
PARP inhibition is one example of researchers exploiting that vulnerability. This illustrates an important feature of precision medicine: the biological change that helps a cancer develop may sometimes also reveal something the cancer depends on.
Targeted therapy in breast cancer now includes approaches for selected cancers carrying BRCA-related alterations, alongside HER2- and hormone-related strategies.
The research challenge is determining which tumors actually depend on that vulnerability and how resistance develops after treatment.
What Connects These Four Directions?
HER2-low treatment, ESR1 mutation–guided endocrine therapy, immunotherapy, and DNA-repair targeting appear to be very different fields.
But the research logic is similar: identify a biological feature → ask whether it matters functionally → develop a way to intervene → identify the patients in whom that intervention has meaningful benefit.
That process requires both sophisticated technology and ordinary laboratory work. Cell models must be maintained. Samples must be processed. Treatment conditions must be compared. Molecular measurements must be performed. Results must be interpreted against appropriate controls.
For compatible luminescence-based treatment comparisons, explore D2L’s Drug Response & Luminescence Assay Essentials Bundle. For selected gene-expression measurements, the Gene Expression & PCR Essentials Bundle supports downstream PCR/qPCR setup after sample preparation and, where applicable, RNA extraction and reverse transcription.
Basic consumables are not the innovation itself. They are part of the experimental infrastructure researchers use to test whether an innovative idea survives contact with real biological data.
Research Essentials
Drug Response & Luminescence Assay Essentials Bundle
For compatible plate-based comparisons of experimental treatment conditions and luminescence readouts.
White-wall / white-bottom 96-well plate
Sterile filter tips for small-volume additions and routine transfers
Sterile reagent troughs
Gene Expression & PCR Essentials Bundle
Downstream PCR setup for selected gene-expression workflows after compatibility review.
Includes: 0.1 mL half-skirted 96-well PCR plates; candidate clear plate-sealing film; 10 µL and 200 µL sterile low-retention filter tips.
